. 2011 Nov 7;30(3):232–238. doi: 10.1200/JCO.2011.38.6565

Table A1.

RR for OS, PFS, EFS and Cumulative Incidence of CCyR, MMR, and CMR, and c-CCyRS at 8 Years According to the Pretherapy Characteristics of the Patients

Variable	OS		PFS		EFS		CCyR		MMR		CMR		c-CCyRS
Variable	RR	P	RR	P	RR	P	RR	P	RR	P	RR	P	RR	P
Age (years)	1.021	.14	1.017	.14	1.006	.36	0.990	.74	1.002	.75	1.013	.23	0.998	.64
Sex (female)	0.983	.96	0.963	.91	1.000	.96	1.142	.31	1.719	.04	6.491	< .001	1.007	.953
Sokal risk group		.002		.003		.27		< .001		.02		.09		< .001
Low	1		1		1		1		1		1		1
Intermediate	2.279		1.646		1.260		0.800		0.814		0.570		0.786
High	5.532		3.944		1.388		0.506		0.622		0.492		0.498
CE	1.655	.5	2.180	.21	0.761	.52	1.171	.51	1.411	.29	1.101	.47	1.096	.75
Splenomegaly (cm)	1.056	.03	1.045	.06	1.029	.007	0.958	< .001	0.938	< .001	0.847	< .001	0.935	< .001
White cell count (×10⁹/L)	1.003	.01	1.002	.05	1.002	< .001	0.997	< .001	0.996	< .001	0.989	< .001	0.998	.01
Platelet count (×10⁹/L)	1.000	.91	1.000	.57	1.001	.006	1.001	.005	1.001	.03	1.001	.001	1.000	.64
Hemoglobin (g/dL)	0.733	.001	0.790	.005	0.878	.01	1.207	< .001	1.221	< .001	1.258	.02	1.116	.001
Peripheral blood blasts (%)	1.082	.07	1.094	.06	1.121	.001	0.928	.005	0.953	.12	0.648	.01	0.964	.11
Peripheral blood basophils (%)	1.058	.25	1.033	.51	0.974	.31	1.023	.18	1.030	.13	1.027	.19	1.017	.34

Abbreviations: c-CCyRS, current complete cytogenetic response survival; CCyR, complete cytogenetic response; CMR, complete molecular response; CE, chromosomal abnormalities in addition to the Philadelphia chromosome; EFS, event-free survival; MMR, major molecular response; OS, overall survival; PFS, progression-free survival; RR, relative risk.